New Swiss Phase 2 Pilot study below [1].
"Twenty-five men with metastatic castration-resistant prostate cancer and prostate-specific antigen (PSA) progression while receiving treatment with abiraterone from 3 Swiss centers were included in this single-arm phase 2 trial between November 2013 and September 2016. Metformin was added to abiraterone continuously at 1000 mg twice daily in uninterrupted 4-week cycles. The primary end point was the absence of disease progression at 12 weeks"
"The primary end point PFS12 was 12% (3 of 25 patients)"
"A higher-than-expected gastrointestinal toxicity attributed to metformin was observed."
Conclusion: "no meaningful clinical benefit".
Some of the team were on the Swiss study that impressed Dr. Myers [2]. That study was "Metformin in chemotherapy-naive castration-resistant prostate cancer". It reported: "Thirty-six percent of patients were progression-free at 12 wk". Seems that after Abi failure, PCa is less responsive to Metformin. Also, perhaps Abi treatment makes the stomach less able to tolerate Metformin.
-Patrick